Quarterly report pursuant to Section 13 or 15(d)

Subsequent Events

Subsequent Events
6 Months Ended
Jun. 30, 2018
Subsequent Events [Abstract]  
Subsequent Events Subsequent Events
In addition to the subsequent events discussed elsewhere in these notes, see below for a discussion of our subsequent events occurring after  June 30, 2018.

In July 2018, the Company announced it has begun pre-clinical toxicology testing of its WP1732, a fully water-soluble STAT3 inhibitor and a candidate to treat pancreatic cancer, through its new subsidiary in Australia. The Company believes that such work will increase future research and development expenses.